Always consult your medical specialist when determining which course of treatment is best for you or your loved ones.
Disclaimer © 2008 RespiratoryTherapist.com.

Respiratory Therapist      

RespiratoryTherapist.com Jobs

Job Title Company Name Job Location Status
Respiratory Therapist CRAssociates, Inc. Alexandria, VA 22309 Full Time

News Feed


Localities asked to take tough action against blue ear disease (Nhân Dân)
Nhan Dan - Localities have been asked to take tough action against blue ear disease (or porcine reproductive and respiratory syndrome - PRRS).
GE Healthcare Signs Global Molecular Diagnostic Agreement to Advance Respiratory Drug Development (Centre Daily Times)
GE Healthcare, a subsidiary of the General Electric Company (NYSE:GE) announced today that it has signed a non-exclusive agreement with Merck & Co., Inc. to share technology on imaging of the lungs that may help to advance respiratory treatment development. Under terms of the agreement, Merck will be granted access to Spin Signal Technology(TM) (SST) utilizing hyperpolarized Xenon 129 gas, a ...
GE Healthcare Signs Global Molecular Diagnostic Agreement to Advance Respiratory Drug Development (Business Wire via Yahoo! Finance)
CHALFONT ST GILES, England----GE Healthcare, a subsidiary of the General Electric Company announced today that it has signed a non-exclusive agreement with Merck & Co., Inc. to share technology on imaging of the lungs that may help to advance respiratory treatment development.
Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting (EurekAlert!)
HONOLULU, HI, May 4, 2008 – MedImmune today announced that researchers are currently presenting results from a MedImmune-sponsored Phase 3 study involving motavizumab, an investigational monoclonal antibody (MAb) that is being evaluated for its potential to prevent serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients.
Study shows physician judgement important in reducing RSV-related hospitalizations (EurekAlert!)
HONOLULU, HI, May 5, 2008 – MedImmune announced today that the company presented results from a retrospective chart review that evaluated the use of Synagis® (palivizumab) as a preventive measure against respiratory syncytial virus (RSV) disease in high-risk infants.
News briefs: May issue of the journal Chest (EurekAlert!)
Previous research has linked the use of long-acting β2-agonists (LABA) to increased risk for adverse events or respiratory-related death in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD); however, a recent article shows this may not be the case.
Motavizumab Cuts RSV Burden In High-Risk Infants (Medical News Today)
The investigational second-generation humanized monoclonal antibody motavizumab significantly decreases hospitalizations due to respiratory syncytial virus (RSV) and outpatient acute lower respiratory tract infections (ALRIs) in term American Indian infants at high risk of RSV disease, according to i

Asthma Stories

Health Store

Take a look at our online skin health store
Skin Health Products



Pari

Google Ads